

October 18, 2017

Insulet and Dexcom Partner to Offer Choices for Animas Users

Insulet's Welcome Program for Animas[®] Users Now Includes Optional Dexcom G5[®] Mobile CGM Upgrade

BILLERICA, Mass--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company) the leader in [tubeless insulin pump](#) technology with its Omnipod[®] Insulin Management System (Omnipod System), is partnering with DexCom, Inc. (Dexcom) to provide the Omnipod System and a \$200 gift card from Dexcom which can be used towards the purchase of a Dexcom G5[®] Mobile CGM (Continuous Glucose Monitoring) for qualified Animas[®] insulin pump users.¹ The program provides Animas users with an easy way to experience freedom from tubing and the ability to dose insulin without finger pricks.

This press release features multimedia. View the full release here:
<http://www.businesswire.com/news/home/20171018006532/en/>

The [Omnipod Welcome Program](#) includes a no cost trial of the Omnipod System, a free box of Pods (10 count), and the opportunity to receive a \$200 gift card for completing a Dexcom patient survey to upgrade to the Dexcom G5 CGM.² Animas pump switchers who have recently taken advantage of the existing Omnipod Welcome Program may still take advantage of this Dexcom offer as long as they are not an already-existing customer of Dexcom.

"We created this program to provide a way for Animas users to experience the freedom of the Omnipod System with the peace of mind of Dexcom's market-leading CGM," said Bret Christensen, Chief Commercial Officer of Insulet. "Managing diabetes is a very personal decision and we strongly support an individual's right to choice when it comes to their diabetes management. This partnership is just one example of our commitment to support people with diabetes today and over the long term."

"Dexcom is excited to partner with Insulet to offer this special promotion," said Rick Doubleday, Chief Commercial Officer of Dexcom. "This provides Animas users the opportunity to upgrade to our best-selling Dexcom G5 Mobile CGM and have easier access to the only tubeless pump system in the U.S."

As the number one pediatric preferred pump³, which is also quickly gaining adoption with adults, the Omnipod System uses a tubeless, waterproof patch-pump technology that offers users significant quality of life benefits. The differentiated design provides up to 72 hours of nonstop, discreet insulin delivery, and more choice for site selection. It eliminates the burden associated with multiple daily injections and the complexity associated with traditional tubed pumps. When used with the Dexcom G5 Mobile CGM, users will benefit from fewer finger sticks, fewer components to carry and wear, and access to pump and blood glucose data from their smart-phone with Insulet provided Glooko.

For full offer details and to get started, Animas patients should call the Insulet Customer Care Team at 1-888-643-8763. Offer terms and conditions are subject to change. Please [click here](#) for full promotion details.

¹The Omnipod Insulin Management System and the Dexcom G5 CGM are not integrated, are sold separately, and function independently.

²These promotions are two independent offerings and therefore an individual may take advantage of either one separately or both. You may be required to submit a form directly to Dexcom.

³dQ&A Q3 2016 Patient Panel Survey. Share of parents of children with type 1 diabetes on an insulin pump who had chosen the Omnipod[®] was higher than for other pumps. Statistical significance of results calculated at the 95% confidence level.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with

diabetes easier. Insulet seeks to expand the use of insulin pump therapy with its Omnipod Insulin Management System among people with insulin-dependent diabetes. The Omnipod System is a revolutionary and easy-to-use tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business partners with global pharmaceutical and biotechnology companies to adapt the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: <http://www.myomnipod.com>.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2017 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

© 2017 Insulet Corporation and Omnipod are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20171018006532/en/>

Investor Relations and Media Contact:

Insulet Corporation
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications
dgordon@insulet.com

Source: Insulet Corporation

News Provided by Acquire Media